- Severe early-onset fetal growth restriction (FGR) is an untreatable condition associated with substantial mortality and morbidity for the fetus and neonate. There has been growing interest in novel therapies such as nitric oxide donors and promotors to improve placental function and outcomes for these high-risk pregnancies. The UK STRIDER trial was designed to test the effectiveness of sildenafil (25 mg three times a day) versus placebo at prolonging gestation in severe early-onset FGR.
- Publication status:
- Peer review status:
- Peer reviewed
- Copyright holder:
- Copyright date:
- Rights statement:
- © 2019 Elsevier Ltd. All rights reserved.
- This is the accepted manuscript version of the article. The final version is available online from Elsevier at: https://doi.org/10.1016/S2352-4642(19)30020-3
Mortality in the UK STRIDER trial of sildenafil therapy for the treatment of severe early-onset fetal growth restriction
If you are the owner of this record, you can report an update to it here: Report update to this record